Related references
Note: Only part of the references are listed.Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith et al.
LANCET ONCOLOGY (2019)
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan A. Rice et al.
FRONTIERS IN ONCOLOGY (2019)
A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer
Sabrina Koecher et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy
Christoph Oing et al.
CANCER LETTERS (2018)
Ten year final results of the TROG 03.04 (RADAR) randomised phase 3 trial evaluating duration of androgen suppression ± zoledronate for locally advanced prostate cancer.
David John Joseph et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies
Dane R. Liston et al.
CLINICAL CANCER RESEARCH (2017)
Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial.
Abdenour Nabid et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair
Firas L. Tarish et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model
H. G. Nguyen et al.
ONCOGENE (2014)
Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer
Firas L. T. Al-Ubaidi et al.
CLINICAL CANCER RESEARCH (2013)
Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma
Wael Y. Mansour et al.
RADIOTHERAPY AND ONCOLOGY (2013)
A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult
Jonathan F. Goodwin et al.
CANCER DISCOVERY (2013)
Chromatin modifications and the DNA damage response to ionizing radiation
Rakesh Kumar et al.
FRONTIERS IN ONCOLOGY (2013)
Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
Juliet Richards et al.
CANCER RESEARCH (2012)
Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells
Harris S. Soifer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials
Anthony V. D'Amico et al.
LANCET ONCOLOGY (2012)
Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer
A. Urbanucci et al.
ONCOGENE (2012)
Current Clinical Trials in Castrate-Resistant Prostate Cancer
Daniel P. Petrylak
Current Urology Reports (2011)
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
Karen E. Knudsen et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2011)
Combining radiation therapy and androgen deprivation for localized prostate cancer—a critical review
L. Souhami et al.
Current Oncology (2010)
Short-term Endocrine Therapy Prior to and during Radiation Therapy Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA <= 20: Initial Results of RTOG 94-08
D. G. McGowan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
FEN1 Functions in Long Patch Base Excision Repair Under Conditions of Oxidative Stress in Vertebrate Cells
Kenjiro Asagoshi et al.
MOLECULAR CANCER RESEARCH (2010)
Androgen suppression and radiation vs radiation alone for prostate cancer - A randomized trial
Anthony V. D'Amico et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
Eric M. Horwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
DNA double-strand break repair: From mechanistic understanding to cancer treatment
Thomas Helleday et al.
DNA REPAIR (2007)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer
J Laverdière et al.
JOURNAL OF UROLOGY (2004)
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02
GE Hanks et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
